T HE HEPATITIS DELTA VlRUS (HDV) lS an incomplete virus requiring the helper function of the hepati tis B virus (HBV) for its expression ( 1.2). HOV can infect a nonimmune host sim ul taneously with H BV (coinfection) or infect an hepatitis B surface an tigen (HBsAg) carrier causing an acute, ch ronic or asymptomatic illness (superinfection). Following the introduction of sensitive methods for detecting HOV antigen and its antibodies it became apparent that HDV infections originally described in southern Italia ns arc worldwid e (2.3). Endemic areas of HDV exist in the eastern Mediterranean a rea, the Middle East, some areas of Africa (4). among the Yucpa Indians in Venezuela (5) and in th e Nauru and oche r isla nds of the western Pac ifi c (6). In western and northern Europe and in the Un ited States, HDV infec ti ons occur mostly in pa renteral drug abusers and hemoph ili acs (7-ll ). HDV infections arc rare among Chinese, despite a high HBsAg carrier rate ( 12).
The a ims o f th is study were to estimate the prevalence of HOV infection in patients with various types of HBV related liver disease in Toronto, On ta rio Of the 18 patients with acute hepatitis, two were intravenous drug abusers and one of them was homosexual. All patients with chronic hepati tis, cirrh osis and hepatocellular carcinoma had liver b iopsies. H istological interpretation was in accordance with the Fogerty classification ( 13 ) . All the asymptomatic carrie rs had no cl inica l evidence of live r disease and had persisten tly normal liver fu nction tests for at least six mon ths. and those with chronic liver disease were :,een monthly. Liver biopsies were performed wh en clinically indicated and delta determinations were done within three to six months of the liver biopsy. Labo ratory tests: Hepatitis B surface antigen, anti-HBsAg . anti-HB core antigen, hepatitis Be antigen, anti-hepatitis Be and lgM anti-H Bc tests were done by commercially available RIA kits (Abbott Pharmaceutical. North Chicago, Ill inois).
Antidelta was measured by the comme rcially avai lable antidelta RIA k it (Abbott P harmaceutical Laboratories) and by blocking RIA in the Division of Molecular Biology and Immuno logy, Georgetown U n iversity. The delta a n tigen was measured by a blocking RIA also at Georgetown Un iversity. A ll sam p les were ana lyzed under code.
RESULTS
Thirteen of th e 216 patients (6.0%) were found to have antidelta in their sera. The distribution of antidelta in the various types of HBV liver disease is shown in Table 2 .
TABLE 2
P atie nts w ith acute h e patitis B: Of 1 patients (ll.1°'<>) with acute hepatitis B.
rwo were found to have delta coinfection One had delta antigen in th e scrum in the first week of illness and one had high levels of antidelta in the second week of the illness. Both we re Canadian-born and both were intravenous drug abusers; one was homosexual. There wasno difference between the clinical presemation of the two patients who were anndelta positive and the 16 who had no evidence of HOV infection. There were no chronic sequelae in either the 16 patients with acute hepa titis B or the two patients with coincident HOV infcc· cion. The only fatal case was negative for H OV infection. Patie nts w ith c hronic live r disease:
Five of th e 30 patients ( 16.7°'o) with ch ronic liver disease had evidence of del ta infection . One of seven patients wi th ch ronic persistent hepatitis had antidelta in the serum; this patient had immigrated from Africa. T hree of the I) patients with chronic active hepatitis had antidclta in the serum; one w::i.s from Italy, one from Malta and one was Canadian· born. The Canadian-born patient was an intravenous drug abuser. All three patients had very severe chronic active hepatitis on liver biopsy. One of the six patients with cirrhosis had an tidclta in th e serum. This patient came from Ger· many, a country where H OV is not e ndemic. The patient denied intravc· nous drug abuse.
A symptom atic c arrie rs: Six of 165 carriers (3 .6%) had evidence of HOV infection. Five of the six carriers were from a group of 108 who were born in areas where HO V is endemic. Two were T he patients selected for study h ad all been referred to the Liver Study Un it at Mount Sinai Hospital, Toron to. The 165 asymptomatic carriers were selected from an HBsAg carrier clinic which has been following 600 carriers for many years. A ll patients who attended the clinic over a period o f n ine mo n ths were tested for antibody to HOV. T hese patients were evaluated every fou r mon ths and have been followed for at least three years. The patients with acute and ch ronic liver d isease were th ose seen in the liver clinic over a period of nin e mo nths. Patients with acute hepatitis were seen weekl y from Italy, one from G reece, one from Turkey and one from Africa. T he ocher patient was from C h ina, a nonendemic area. None of these patients were drug users.
DISCUSSION
The prevalence of HOV infection was 6':o in the 216 patients studied. The three patients in this study who had evidence of HOV infection and who were born in Canada we re all intravenous drug abusers. The majority of patients (eight of 10) with HOV infection who were born outside of Canada came from cou ntries where HOV infection is endemic. None of these were drug abusers. A previous Canadian study also fo u nd ch at, where HOV infection was present, it was almost exclusively in immigrants from countries where HOV infection is endemic{l4). ln chacscudy, serum ancidclca was done in 326 HBsAg positive patients. The group consisted of 216 Indochinese refugees, 46 patients with acute hepatitis, 39 blood donors and 25 patie n ts at high risk fo r hepatitis (homosexuals, patients with hemoph ilia and drug abusers). Eight serum samples were positive for antidel,., (2.4%). Seven were from Indochinese refugees whose samples were obtained on arrival in Can ada and one from a homosexual male with no history of drug abuse. This was a serological survey only and the cli n ical and histological status of the immigrants was not mentioned in the report ( 14).
The high prevalence of antibody to HDV in the Indochinese immigrants in the aforementioned study compared to the low prevalence in the Asian group in the present study is probably due to the different areas of origi n of the two groups. Almost aU the Asians in the present group were from mainland C h ina or Hong Kong rather than from Indo- (Table 2 ). Boch were intravenous d rug abusers. Acute hepatitis due co coinfection with HDV and HBV is seen commonly in intravenous drug abusers both in countries where delta infection is e ndemic (7-9) as well as in countries like Canada where there is a low prevalence of HOV infection ( 15.18.19) . In endemic areas HOV is also common in the absence of intravenous drug abuse and in these areas transmission may be by inapparent permucosal or percutaneous routes (20) .
The acute ill ness in the patients in th is study with HBV and HOV coinfeccion was not more severe than in che 16 patients who had hepatitis B alone and no patient in either group developed ch ron ic hepatitis. Oth er studies have shown that acute coinfeccion with HBV and HOV does not result in chronic hepatitis more commonly than in patients who have acute hepatitis B alone ( 18, 21) . The reason for chis is chat when HBV and HDV infection are acqui red simultaneously, che HDV infection cannot outlast the HBV infection (22). ln this study, the patient with fulminanc hepatitis had no markers of HOV infection. However, other studies have shown a h igh prevalence of delta markers in patients with fulm inant hepatitis (5,23). This is not a universal fi nding. In a report from the Mayo Clinic none of eigh t patie n ts with fulminant hepatitis had delta markers ( 15) .
Chronic HOV infection is seen more commonly when HOV infection is superimposed on chron ic HBV infections than when coinfection occurs. Superinfection in an H BsAg carrier may be subclinical or present as acute hepatitis. It frequen tly causes progression of liver injury and an asymptomatic carrier or one with chronic persistent hepatitis can be converted to a carrier with chronic active hepatitis and cirrhosis (24) . ln patients with chronic delta hepatitis, chronic active hepatitis is che most common histological lesion seen (22.25). In the present.study five of 30 patients with ch ronic hepatitis B had evidence of delta infectio n . Three of the five had chronic active hepatitis and all three had severe disease o n liver biopsy (Table 2) . There is considerable difference in the prevalence of delta infection in ch ro ni c live r disease in different pares of th e world (Table 3) . ln countries with a low prevale n ce of delta infection, such as West Germany ( 19) and C h ina ( 12,26), delta infection in patients with chron ic liver disease due co HBV is uncommon, while in endemic areas, such as Italy (27), it is common. The reasons fo r the difference in prevalence of HOV markers in patients with chronic acti ve hepati tis in ch e reported studies are not known. They may be related to difference in freq uency of drug abuse, the geographic origin of the patients or the extent of liver damage prior co the delta superinfection. le is evident chat HOV superinfection of patien ts with ch ronic hepatitis B is an im portant contribu tor to chronic liver d isease in some pares of the world but plays a negligible role in ocher areas.
The n umber of patien ts with cirrhosis and hepatocellu lar carcinoma in chis study was too small to estimate the importance of HOV in fectio n in thei r pathogenesis. In a nother stu dy, coincident HDV infection did not appear to increase FEINMAN ct a/ rhc frequency of hepati tis B rdatcd carcinoma (28).
In the asymptomatic carriers in this study, 3.6% haJ HDV markers. The p revalence of HD V markers in !08 patients born in countries with a high prevalence of H OV was 4.6"(,. This approximates the pn:valcncc in asymptomatic HBsAg carriers in an en d em ic a rea suc h ns I ta ly (6. 4''.,) (28) . In 57 patien ts born in countries wirh a low prevale nce it was on ly l. 7"t 
